Budget Amount *help |
¥17,420,000 (Direct Cost: ¥13,400,000、Indirect Cost: ¥4,020,000)
Fiscal Year 2022: ¥6,630,000 (Direct Cost: ¥5,100,000、Indirect Cost: ¥1,530,000)
Fiscal Year 2021: ¥6,110,000 (Direct Cost: ¥4,700,000、Indirect Cost: ¥1,410,000)
Fiscal Year 2020: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
|
Outline of Final Research Achievements |
Glioblastoma (GBM) is the most common high-grade malignant glioma in adults. Emerging evidence indicates that glioma-initiating cell (GICs) contribute to glioblastoma initiation, progression and recurrence owing to their self-renewal capacity and tumorigenicity. SMAD specific E3 ubiquitin protein ligase 2 (SMURF2) belongs to the E3 ubiquitin ligase family. We have previously demonstrated that phosphorylation of SMURF2 at Thr249 activates its E3 ubiquitin ligase activity. Here, we show that the importance of SMURF2Thr249 phosphorylation in maintenance of stemness and tumorigenicity of GICs, and a potential target for GIC-directed therapy.
|